Shared by
beno
Fundamentals
Shares Outstanding: 54,815,202
Cash: $345.1m
Current liabilities: $111.36m
Current ratio: 3.75
NWC (total current assets - total current liabilities): $307m
Monthly Burn rate (net loss / months): $33.43m
Estimated current cash: $295m
Accumulated deficit: $2144m
Book value per share (Stock holder equity / Shares outstanding): $-1.6
Catalysts / News / Painting the picture
-Earnings: Q3 loss but beat on revenues
-Clovis Oncology’s Rubraca® (rucaparib) Granted FDA Priority Review for Advanced Prostate Cancer
Technical Analysis
-Gap up to 11.50 on FDA priority news
-Very clean down trend all day
-Levels: 9.50, 10, 10.50
Original Plan / Strategy
First Test Short of 10
Review
3 lots got filled but I didn't hold 1/3 for a bigger move because I wanted to be conservative in order to have a green day (I would have made more money today had I stuck to my plan of holding 1/3 to 1/2 for longer!
Lessons learned: stick to the plan and hold 1/3 to 1/2 for bigger move!
Execution detail:
| Date/time | Symbol | Side | Price | Position |
|---|---|---|---|---|
| 2020-01-15 12:26:32 | CLVS | sell | $9.990 | short |
| 2020-01-15 12:27:10 | CLVS | sell | $10.010 | short |
| 2020-01-15 12:30:29 | CLVS | sell | $10.030 | short |
| 2020-01-15 12:32:29 | CLVS | buy | $9.940 | short |
| 2020-01-15 12:32:42 | CLVS | buy | $9.950 | 0 |
| 2020-01-15 13:28:11 | CLVS | sell | $9.750 | short |
| 2020-01-15 13:31:11 | CLVS | buy | $9.707 | 0 |
Leave a comment about this trade!
You need to log into your Tradervue account to leave a comment. If you don't have one,
it takes
just a few seconds to sign up, and it's free!